GALAPAGOS NV |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.96 EUR | -1.03% |
|
-1.39% | -27.12% |
| May. 03 | Transcript : Galapagos NV, Q1 2024 Earnings Call, May 03, 2024 | |
| May. 02 | Galapagos NV Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presenter SpeechJames Gordon (Analysts)Good afternoon. I'm James Gordon, J.P. Morgan European ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
27.24
EUR
Average target price
37.03
EUR
Spread / Average Target
+35.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.12% | 1.93B | |
| +22.30% | 46.4B | |
| -1.15% | 41.75B | |
| +47.75% | 41.37B | |
| -3.52% | 29.71B | |
| +10.12% | 26.01B | |
| -19.95% | 19.52B | |
| +30.70% | 12.43B | |
| +0.26% | 12.18B | |
| -0.04% | 12.13B |
- Stock Market
- Equities
- GLPG Stock
- News Galapagos NV
- Transcript : Galapagos NV Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 04